Striving for Kinder & Gentler ADCs: Spotlighting Solid Tumor Target & Preclinical Development of KIVU-107
- Unveiling preclinical characterization and targeting of KIVU-107 against solid tumors
- Exploring rationale behind KIVU-107 target selection strategy
- Laying out differentiation strategy and philosophy behind kinder and gentler ADCs, emphasizing the importance of tolerability in therapeutic index